Abstract
Objective
We aimed to evaluate the relationship between circulating blood adipokine levels and systemic sclerosis (SSc).
Methods
We conducted a meta-analysis on serum/plasma adiponectin, leptin, or resistin levels in patients with SSc and controls, and performed a subgroup analysis based on ethnicity and/or disease type.
Results
Eleven studies (511 patients with SSc and 341 controls) were included in the meta-analysis. Meta-analysis revealed that adiponectin levels were significantly lower in patients with SSc than in controls (standardized mean differences [SMD] = −0.638; 95 % confidence intervals [CI] = −1.154, −0.122; P = 0.015). Stratification by ethnicity showed a low adiponectin level associated with SSc in Caucasians (SMD = −0.439; 95 % CI = −1.092, −0.213; P = 0.187) and Asians (SMD = −1.006; 95 % CI = −2.031, −0.019; P = 0.055), although this result was not statistically significant. Stratification by disease type revealed that the adiponectin level was significantly lower in the diffuse SSc, but not limited SSc, group than in the control (diffuse: SMD = −1.445; 95 % CI = −2.276, −0.614; P = 0.001; limited: SMD = 0.188; 95 % CI = −0.064, 0.439; P = 0.144). Meta-analysis showed no association between leptin levels and SSc (SMD = −0.029; 95 % CI = −1.362, 1.304; P = 0.966), and no association between resistin levels and SSc (SMD = 0.202; 95 % CI = −0.091, 0.496; P = 0.177).
Conclusions
Our meta-analysis revealed a significantly lower circulating adiponectin level in patients with SSc than in controls. This difference was apparent in the diffuse type of SSc, but not in the limited type. However, circulating leptin and resistin levels were not different between patients with SSc and healthy controls.
Zusammenfassung
Ziel
Ziel war es, die Beziehung der Plasmaspiegel von zirkulierendem Adiponectin und systemischer Sklerose (SSc) zu beurteilen.
Methoden
Die Autoren führten eine Metaanalyse über Serum-/Plasmaspiegel von Adiponectin, Leptin oder Resistin bei Patienten mit SSc und einer Kontrollgruppe durch. Es erfolgte eine Subgruppenanalyse, die auf Ethnizität und/oder Krankheitstyp basierte.
Ergebnisse
Elf Studien (511 Patienten mit SSc und 341 Kontrollpersonen) wurden in die Metaanalyse eingeschlossen. Die Metaanalyse zeigte, dass der Adiponectinspiegel bei Patienten mit SSc signifikant niedriger war als in der Kontrollgruppe (standardisierte Mittelwertsdifferenz [SMD] = −0,638; 95 % Konfidenzintervall [CI] = −1,154 bis −0,122; p = 0,015). Die Stratifizierung nach Ethnizität zeigte eine Assoziation zwischen einem niedrigen Adiponectinspiegel und Personen mit weißer Hautfarbe (SMD = −0,439; 95 % CI = −1,092 bis −0.213; p = 0.187) sowie Asiaten (SMD = −1,006; 95 % CI = −2,031 bis −0.019; p = 0,055), obwohl dieses Ergebnis nicht statistisch signifikant war. Die Stratifizierung nach Krankheitstyp zeigte, dass der Adiponectinspiegel signifikant niedriger in der Gruppe mit diffuser, jedoch nicht mit limitierter SSc war als in der Kontrollgruppe (diffuse SSc: SMD = −1,445; 95 % CI = −2,276 bis −0,614; p = 0,001; limitierte SSc: SMD = 0,188; 95 % CI = −0,064 bis 0,439; p = 0,144). Die Metaanalyse zeigte keinen Zusammenhang zwischen dem Leptinspiegel und SSc (SMD = −0,029; 95 % CI = −1,362 bis 1,304; p = 0,966) sowie keinen Zusammenhang zwischen dem Resistinspiegel und SSc (SMD = 0,202; 95 % CI = −0,091 bis 0,496; p = 0,177).
Schlussfolgerung
Unsere Metaanalyse zeigte einen signifikant niedrigeren Plasmaspiegel von Adiponectin bei Patienten mit SSc als in der Kontrollgruppe. Dieser Unterschied war bei der diffusen SSc ersichtlich, aber nicht bei der limitierten SSc. Bei den Plasmaspiegeln von zirkulierendem Leptin und Resistin gab es jedoch keinen Unterschied zwischen Patienten mit SSc und der Kontrollgruppe.
Similar content being viewed by others
References
Gabrielli A, Avvedimento EV, Krieg Scleroderma T (2009) Scleroderma. N Engl J Med 360(19):1989–2003
Coelho M, Oliveira T, Fernandes R (2013) Biochemistry of adipose tissue: an endocrine organ. Arch Med Sci 9(2):191–200
Shehzad A, Iqbal W, Shehzad O, Lee YS (2012) Adiponectin: regulation of its production and its role in human diseases. Hormones 11(1):8–20
Kelesidis T, Kelesidis I, Chou S, Mantzoros CS (2010) Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med 152(2):93–100
Conde J, Scotece M, Gómez R, López V, Gómez-Reino JJ, Lago F et al (2011) Adipokines: biofactors from white adipose tissue. A complex hub among inflammation, metabolism, and immunity. Biofactors 37(6):413–420
Fernández-Riejos P, Najib S, Santos-Alvarez J, Martín-Romero C, Pérez-Pérez A, González-Yanes C et al (2010) Role of leptin in the activation of immune cells. Mediators Inflamm 2010:Article ID 568343. doi:10.1155/2010/568343
Gabay C, Dreyer M, Pellegrinelli N, Chicheportiche R, Meier CA (2001) Leptin directly induces the secretion of interleukin 1 receptor antagonist in human monocytes. J Clin Endocrinol Metab 86(2):783–791
Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A (2005) Resistin, an adipokine with potent proinflammatory properties. J Immunol 174(9):5789–5795
Olewicz-Gawlik A, Danczak-Pazdrowska A, Kuznar-Kaminska B, Batura-Gabryel H, Katulska K, Wojciech S et al (2015) Circulating adipokines and organ involvement in patients with systemic sclerosis. Acta Reumatol Port 40(2):156–162
Winsz-Szczotka K, Kuznik-Trocha K, Komosinska-Vassev K, Kucharz E, Kotulska A, Olczyk K (2014) Relationship between adiponectin, leptin, IGF-1 and total lipid peroxides plasma concentrations in patients with systemic sclerosis: possible role in disease development. Int J Rheum Dis. doi:10.1111/1756-185x.12332
Budulgan M, Dilek B, Dag SB, Batmaz I, Yildiz I, Sariyildiz MA et al (2014) Relationship between serum leptin level and disease activity in patients with systemic sclerosis. Clin Rheumatol 33(3):335–339
Masui Y, Asano Y, Akamata K, Aozasa N, Noda S, Taniguchi T et al (2014) Serum resistin levels: a possible correlation with pulmonary vascular involvement in patients with systemic sclerosis. Rheumatol Int 34(8):1165–1170
Lakota K, Wei J, Carns M, Hinchcliff M, Lee J, Whitfield ML et al (2012) Levels of adiponectin, a marker for PPAR-gamma activity, correlate with skin fibrosis in systemic sclerosis: potential utility as biomarker? Arthritis Res Ther 14(3):R102
Tomcik M, Arima K, Hulejova H, Kuklova M, Filkova M, Braun M et al (2012) Adiponectin relation to skin changes and dyslipidemia in systemic sclerosis. Cytokine 58(2):165–168
Arakawa H, Jinnin M, Muchemwa FC, Makino T, Kajihara I, Makino K et al (2011) Adiponectin expression is decreased in the involved skin and sera of diffuse cutaneous scleroderma patients. Exp Dermatol 20(9):764–766
Masui Y, Asano Y, Shibata S, Noda S, Aozasa N, Akamata K et al (2012) Serum adiponectin levels inversely correlate with the activity of progressive skin sclerosis in patients with diffuse cutaneous systemic sclerosis. J Eur Acad Dermatol Venereol 26(3):354–360
Pehlivan Y, Onat AM, Ceylan N, Turkbeyler IH, Buyukhatipoglu H, Comez G et al (2012) Serum leptin, resistin and TNF-alpha levels in patients with systemic sclerosis: the role of adipokines in scleroderma. Int J Rheum Dis 15(4):374–379
Kotulska A, Kucharz EJ, Brzezinska-Wcislo L, Wadas U (2001) A decreased serum leptin level in patients with systemic sclerosis. Clin Rheumatol 20(4):300–302
Riccieri V, Stefanantoni K, Vasile M, Macrì V, Sciarra I, Iannace N et al (2011) Abnormal plasma levels of different angiogenic molecules are associated with different clinical manifestations in patients with systemic sclerosis. Clin Exp Rheumatol 29(2 Suppl 65):46–52
Lee YH, Woo JH, Choi SJ, Ji JD, Song GG (2009) Associations between osteoprotegerin polymorphisms and bone mineral density: a meta-analysis. Mol Biol Rep 37(1):227–234
Lee YH, Rho YH, Choi SJ, Ji JD, Song GG (2007) PADI4 polymorphisms and rheumatoid arthritis susceptibility: a meta-analysis. Rheumatol Int 27(9):827–833
Lee YH, Woo JH, Choi SJ, Ji JD, Song GG (2010) Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis. Lupus 19(6):703–710
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097
Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5:13
Wells G, Shea B, O’connell D, Peterson J, Welch V, Losos M et al (2000) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
Egger M, Smith GD, Phillips AN (1997) Meta-analysis: principles and procedures. BMJ 315(7121):1533–1537
DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188
Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558
Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634
Duval S, Tweedie R (2000) Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56(2):455–463
Masui Y, Asano Y, Takahashi T, Shibata S, Akamata K, Aozasa N et al (2013) Clinical significance of monitoring serum adiponectin levels during intravenous pulse cyclophosphamide therapy in interstitial lung disease associated with systemic sclerosis. Mod Rheumatol 23(2):323–329
Fang F, Liu L, Yang Y, Tamaki Z, Wei J, Marangoni RG et al (2012) The adipokine adiponectin has potent anti-fibrotic effects mediated via adenosine monophosphate-activated protein kinase: novel target for fibrosis therapy. Arthritis Res Ther 14(5):R229
Ouedraogo R, Gong Y, Berzins B, Wu X, Mahadev K, Hough K et al (2007) Adiponectin deficiency increases leukocyte-endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo. J Clin Investig 117(6):1718–1726
Schöndorf T, Maiworm A, Emmison N, Forst T, Pfützner A (2005) Biological background and role of adiponectin as marker for insulin resistance and cardiovascular risk. Clin Lab 51(9–10):489–494
Gómez R, Conde J, Scotece M, Gómez-Reino JJ, Lago F, Gualillo O (2011) What’s new in our understanding of the role of adipokines in rheumatic diseases? Nat Rev Rheumatol 7(9):528–536
Otero M, Lago R, Gomez R, Dieguez C, Lago F, Gómez-Reino J et al (2006) Towards a pro-inflammatory and immunomodulatory emerging role of leptin. Rheumatology 45(8):944–950
Iikuni N, Lam QL, Lu L, Matarese G, La Cava A (2008) Leptin and inflammation. Curr Immunol Rev 4(2):70–79
Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI (1998) Leptin modulates the T‑cell immune response and reverses starvation-induced immunosuppression. Nature 394(6696):897–901
Wronkowitz N, Romacho T, Sell H, Eckel J (2014) Adipose tissue dysfunction and inflammation in cardiovascular disease. Front Horm Res 43:79–92
Acknowledgements
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Y.H. Lee and G.G. Song state that they have no competing interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
Additional information
Redaktion
U. Müller-Ladner, Bad Nauheim
U. Lange, Bad Nauheim
Rights and permissions
About this article
Cite this article
Lee, Y.H., Song, G.G. Meta-analysis of circulating adiponectin, leptin, and resistin levels in systemic sclerosis. Z Rheumatol 76, 789–797 (2017). https://doi.org/10.1007/s00393-016-0172-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00393-016-0172-5